Personalized medicine policy challenges: measuring clinical utility at point of care. (June 2012)

• Record Type: Journal Article
• Authors: van Rooij, Tibor; Wilson, Donna M; Marsh, Sharon
• Is Part Of: Expert review of pharmacoeconomics & outcomes research. Volume 12:Number 3(2012)
• Page Start: 289
• Page End: 295
• Publication Date: 2012-06
• Subjects: case studies -- clinical uptake -- economic evaluation -- genomics -- information technology -- patient outcomes -- personalized medicine -- pharmacogenomics -- point of care -- policy change; Pharmacology -- Economic aspects -- Periodicals; 338.47615105
• DOI: 10.1586/erp.12.15
• Languages: English
• ISSNs: 1473-7167

Abstract

Pharmacogenomics, driven by advances in genomics, helps to explain patients' individual variability in response to therapies. Personalized medicine, the application of the increasing understanding of pharmacogenomics, and information technology are intertwined from discovery to delivery at point of care, through to tracking clinical outcomes. Although exemplary cases of personalized medicine adoption demonstrate patient benefit and cost–effectiveness, a remaining barrier to large-scale real-world uptake of this novel approach in medicine is policy change. At point-of-care implementation, case studies will need to measure personalized medicine application outcomes of relevance to policy-makers and as evidence of clinical utility. Assessments need to be consistent across case studies. Standardizing specifications for case studies will better inform policy-makers performing economic evaluations on the use of personalized medicine.